Intra-Cellular Therapies' stock (ITCI) surged over 35% in premarket trading on Monday, poised for its best-ever open and a record high, even as broader market futures grappled with weak tech stock ...

Following this news announcement, shares of Intra-Cellular Therapies rallied 34% on Monday. In the past year, the stock has skyrocketed nearly 92% against the industry’s 16% fall.

Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in a deal that values the company at $14.6 billion. The acquisition includes FDA-approved CAPLYTA for schizophrenia and ...

Investment analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research report issued to clients and investors on Wednesday.

Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and […] Stock analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies ...

Intra-Cellular Therapies continued to post strong gains in Caplyta sales. In its Q3 2024 report, the company recorded net product sales of $175.2 million, up 39% from the same quarter in 2023.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. Its flagship drug, ...

Intra-Cellular Therapies stock leapt more than 30% Monday morning, after Johnson & Johnson agreed to buy the biopharmaceutical company for $132 a share. J&J stock rose 1%. Read more: ...

In a report released today, Jeffrey Hung from Morgan Stanley downgraded Intra-Cellular Therapies (ITCI – Research Report) to a Hold, with a price target of $132.00. Discover outperforming stocks ...